Till innehåll

Oncopeptalks

Oncopeptalks is Oncopeptides’ podcast for investors – a forum where we share insights about the company’s research, clinical programs and growth journey. With the goal of increasing transparency towards the investor community, we discuss current events, scientific advances and the people who drive Oncopeptides forward. New episodes are published regularly in connection with the company’s news and milestones.

Link to transcripts in English

November 12, 2026
Comment on the Q3 Report and EU approval for third line treatment

CEO Sofia Heigis and CFO Henrik Bergentoft comment on the Q3 report – sales up 41 percent to SEK 28.5 million and, for the first time, more than SEK 100 million in rolling twelve-month sales – and on the EU approval for the third line of treatment, which doubles the addressable patient population, how the launch looks in Germany, Italy and Spain, and why the German price negotiation affects the rest of Europe.

Podcast in Swedish only, follow this link for transcripts in Swedish and English:
https://oncopeptalks.com

Listen to episode
October 14, 2026
The breakthrough in glioblastoma – Oncopeptides on the new study data

On October 9, Oncopeptides presented exciting and important new data from its INSULA study in glioblastoma – an aggressive form of brain cancer. The results show that the company’s drug candidate successfully crosses the challenging blood-brain barrier, reaches the tumor tissue as expected, and has so far been well tolerated by patients.

Successfully crossing the blood-brain barrier is a major milestone in cancer research, as no fewer than 90% of all drug candidates in this field fail at precisely this hurdle. What does this breakthrough actually mean for future treatments and for the company’s investors? How does the company’s PDC platform differ from today’s standard treatments, and what is the next step in the clinical development?

To explain the concepts, discuss the new analyses, and talk about the recently announced directed share issue, we are joined by Oncopeptides CEO Sofia Heigis and Chief Medical Officer Stefan Norin.

Podcast in Swedish only, follow this link for transcripts in Swedish and English:
https://oncopeptalks.com

Listen to episode
September 25, 2026
Small team, major impact: behind the scenes of an EMA application

On September 17, it was announced that the EMA’s scientific committee, the CHMP, had issued a positive opinion on expanding the indication for Oncopeptides’ multiple myeloma drug to earlier lines of treatment. The change means that the requirement for patients to be triple-class refractory will be removed.
In this episode, we meet Mette Palm, Head of Regulatory Affairs at Oncopeptides. She explains how she and her colleague Maja prepared, in a short period of time, an application that prompted just one question from the regulatory authority. We also discuss why the company previously chose to focus on later lines of treatment, what has changed since then, and the steps that remain before the European Commission makes its final decision.

Podcast in Swedish only, follow this link for transcripts in Swedish and English:
https://oncopeptalks.com

Listen to episode
August 27, 2026
Commentary on the Second Quarter 2026 Report

CEO Sofia Heigis and CFO Henrik Bergentoft share their perspectives on Oncopeptides’ second-quarter 2026 report, including 62 percent growth, the newly signed distribution agreement with Salus Group for Central and Eastern Europe, and the recently submitted type II variation to the EMA that could expand Pepaxti’s addressable patient population by up to twofold. They also discuss progress in the glioblastoma study in Oslo, where the first patient has now been dosed.

Podcast in Swedish only, follow this link for transcripts in Swedish and English:
https://oncopeptalks.com

Listen to episode
July 6, 2026
Oncopeptides then and now

Jakob Lindberg has followed and led major parts of Oncopeptides’ journey – as CEO when he joined in 2011, later as Chief Science Officer, and today as a scientific advisor.

It is a journey that began in a small, unmanned room at the Karolinska Institute with a promising discovery on how to improve a class of chemotherapy called alkylating agents. This path took him through one of the most extraordinary episodes in Swedish biotech history: the withdrawal of the company’s drug from the US market and a simultaneous European approval – based on the exact same data.

What has he learned along the way? How does he view Oncopeptides’ position today, in the midst of a rapidly changing myeloma landscape? And what will it take for the company to succeed moving forward – not least with its new brain tumor program?

Podcast in Swedish only, follow this link for transcripts in Swedish and English:
https://oncopeptalks.com

Listen to episode
Select language or region
Region

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Learn more about the company Oncopeptides and the work we do to redefine cancer care